India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties ...

Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...

The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Biocon’s share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE).